Markets
The World’s 50 Largest Pharmaceutical Companies
The World’s 50 Largest Pharmaceutical Companies
Globally, big pharma revenues have grown by more than half a trillion dollars since 2012, driven by an aging global population.
American drugmakers make up the greatest market share worldwide by far, supported by high prices in a less regulated market. Yet with 190 drug patents expiring in the next decade, many companies face steep revenue losses at the hands of generic competitors.
This graphic, from Pranav Gavali, shows the largest pharmaceutical companies in the world.
Ranked: The Top 50 Pharmaceutical Giants
Together, the 50 biggest drugmakers make up a combined $4.7 trillion in market capitalization.
With a market cap of over $578 billion, American pharmaceutical company Eli Lilly is the world’s most valuable, known for diabetes medications and its newly-launched weight-loss drug. The average price of insulin in the U.S. is more than five times higher than other countries.
Ranking | Name | Symbol | Market Cap Oct 16 2023 | Country |
---|---|---|---|---|
1 | Eli Lilly | LLY | $578.3B | 🇺🇸 U.S. |
2 | Novo Nordisk | NVO | $452.8B | 🇩🇰 Denmark |
3 | Johnson & Johnson | JNJ | $377.7B | 🇺🇸 U.S. |
4 | Merck | MRK | $263.9B | 🇺🇸 U.S. |
5 | AbbVie | ABBV | $261.2B | 🇺🇸 U.S. |
6 | Roche | ROG.SW | $222.4B | 🇨🇭 Switzerland |
7 | AstraZeneca | AZN | $212.2B | 🇬🇧 UK |
8 | Novartis | NVS | $201.1B | 🇨🇭 Switzerland |
9 | Pfizer | PFE | $181.3B | 🇺🇸 U.S. |
10 | Amgen | AMGN | $152.0B | 🇺🇸 U.S. |
11 | Sanofi | SNY | $138.5B | 🇫🇷 France |
12 | Bristol-Myers Squibb | BMY | $118.0B | 🇺🇸 U.S. |
13 | Gilead Sciences | GILD | $96.8B | 🇺🇸 U.S. |
14 | Vertex Pharmaceuticals | VRTX | $95.8B | 🇺🇸 U.S. |
15 | CVS Health | CVS | $91.9B | 🇺🇸 U.S. |
16 | Regeneron Pharmaceuticals | REGN | $91.1B | 🇺🇸 U.S. |
17 | Zoetis | ZTS | $80.3B | 🇺🇸 U.S. |
18 | GlaxoSmithKline | GSK | $76.6B | 🇬🇧 UK |
19 | CSL | CSL.AX | $73.3B | 🇦🇺 Australia |
20 | Merck KGaA | MRK.DE | $67.8B | 🇩🇪 Germany |
21 | Daiichi Sankyō | 4568.T | $51.7B | 🇯🇵 Japan |
22 | Chugai Pharmaceutical | 4519.T | $50.8B | 🇯🇵 Japan |
23 | Takeda Pharmaceutical | TAK | $47.2B | 🇯🇵 Japan |
24 | Bayer | BAYZF | $45.1B | 🇩🇪 Germany |
25 | Seagen | SGEN | $40.2B | 🇺🇸 U.S. |
26 | Jiangsu Hengrui Medicine | 600276.SS | $38.6B | 🇨🇳 China |
27 | Biogen | BIIB | $38.0B | 🇺🇸 U.S. |
28 | Moderna | MRNA | $37.4B | 🇺🇸 U.S. |
29 | WuXi AppTec | 2359.HK | $36.0B | 🇨🇳 China |
30 | Lonza | LONN.SW | $34.2B | 🇨🇭 Switzerland |
31 | Sun Pharmaceutical | SUNPHARMA.NS | $32.8B | 🇮🇳 India |
32 | Argenx | ARGX | $29.9B | 🇳🇱 Netherlands |
33 | West Pharmaceutical | WST | $28.4B | 🇺🇸 U.S. |
34 | WuXi Biologics | WXXWY | $26.7B | 🇨🇳 China |
35 | Horizon Therapeutics | HZNP | $26.6B | 🇮🇪 Ireland |
36 | BioNTech | BNTX | $24.8B | 🇩🇪 Germany |
37 | Astellas Pharma | 4503.T | $22.9B | 🇯🇵 Japan |
38 | Genmab | GMAB | $21.1B | 🇩🇰 Denmark |
39 | Alnylam Pharmaceuticals | ALNY | $21.0B | 🇺🇸 U.S. |
40 | ICON plc | ICLR | $20.3B | 🇮🇪 Ireland |
41 | Walgreens Boots Alliance | WBA | $20.1B | 🇺🇸 U.S. |
42 | BeiGene | BGNE | $19.5B | 🇨🇳 China |
43 | Otsuka Holdings | 4578.T | $18.4B | 🇯🇵 Japan |
44 | LabCorp | LH | $17.9B | 🇺🇸 U.S. |
45 | Royalty Pharma | RPRX | $16.8B | 🇬🇧 UK |
46 | BioMarin Pharmaceutical | BMRN | $16.2B | 🇺🇸 U.S. |
47 | Baxter | BAX | $16.1B | 🇺🇸 U.S. |
48 | UCB | UCB.VI | $16.0B | 🇧🇪 Belgium |
49 | Eisai | 4523.T | $15.9B | 🇯🇵 Japan |
50 | Celltrion | 068270.KS | $15.0B | 🇰🇷 South Korea |
Ranking in second is Denmark’s Novo Nordisk, with a $453 billion market cap.
The 100-year old company began by making insulin, a newly discovered drug in the 1920s. Like Eli Lilly, it recently launched a weight-loss drug, Ozempic, originally used to treat diabetes. As drug sales soared, the company briefly became the most valuable in Europe.
According to BMO, the weight-loss drug market will be worth $100 billion by 2035.
As a major drug exporter to the U.S., Japan is home to the largest pharma companies in Asia. In fact, it is the third-largest pharmaceutical market in the world. A number of large U.S. pharma companies including Eli Lilly, Pfizer, and Bristol Myers Squibb have subsidiaries in the country.
Of the top 50 pharma companies, U.S. drugmakers make up 56% of global market capitalization, followed by Europe at 34%, and Asia with a 10% market share.
Facing a Cliff
With scores of patents set to expire by 2030, big pharma companies could see a $200 billion loss in revenues due to fierce competition from generics.
As a result, the 10 largest pharmaceutical companies globally are at risk of losing 46% of revenues. Adding to this, the U.S. government announced they may remove patent protection if certain drugs are too expensive in efforts to clamp down on high drug prices.
This may come as a benefit to consumers, especially in America. With some of the highest prescription costs in the world, they are as much as three times more expensive than other countries, averaging $1,432 per person in 2021.
The median price for newly-launched drugs in the U.S. in 2022 was over $200,000 per year—up from $2,115 in 2008.
This article was published as a part of Visual Capitalist's Creator Program, which features data-driven visuals from some of our favorite Creators around the world.
Markets
Visualizing The S&P 500’s Domestic and Foreign Revenues
In 2023, foreign sales made up 28% of the S&P 500’s revenue. Which sector was the most exposed to foreign sales?
Visualizing The S&P 500’s Domestic and Foreign Revenues
This was originally posted on our Voronoi app. Download the app for free on iOS or Android and discover incredible data-driven charts from a variety of trusted sources.
As tariffs remain top of mind ahead of the upcoming U.S. election, some American industries may be more vulnerable to price fluctuations stemming from these trade policies.
Sectors reliant on foreign revenue are particularly vulnerable to the potential impact of stricter tariffs—a policy that Republican presidential candidate Donald Trump has consistently proposed.
This chart visualizes the share of S&P 500’s revenues that come from foreign and domestic sales, broken down by sector.
The data comes from a Goldman Sachs report via ZeroHedge and is updated as of June 2024.
How Much S&P 500 Revenues Come From Foreign Sources
Below, we show the breakdown of the S&P 500’s revenue between domestic and foreign sources in 2023.
Sector | Total Revenues ($bn) | Foreign Revenues ($bn) | Foreign Sales Exposure (%) | Explicit Emerging Market (EM) Sales Exposure (%) |
---|---|---|---|---|
Information Technology | $1,601 | $942 | 59% | 17% |
Materials | $469 | $221 | 47% | 12% |
Energy | $1,301 | $469 | 36% | 3% |
Industrials | $1,666 | $531 | 32% | 5% |
Communication Services | $1,236 | $369 | 30% | 2% |
Consumer Discretionary | $2,011 | $546 | 27% | 3% |
Consumer Staples | $2,211 | $576 | 26% | 3% |
Real Estate | $154 | $36 | 23% | 3% |
Financials | $1,973 | $437 | 22% | 1% |
Health Care | $3,039 | $419 | 14% | 1% |
Utilities | $420 | $10 | 2% | 2% |
S&P 500 | $16,082 | $4,556 | 28% | 4% |
While foreign revenues made up just 28% of the S&P 500’s revenues in 2023, some sectors are more exposed to foreign sales than others.
The S&P 500’s information technology sector had the largest exposure to foreign sales, with 59% of its revenue coming from foreign sources–more than double the index’s average. The index’s information technology category includes big tech firms such as Apple, Nvidia, and Microsoft.
The IT sector of the S&P 500 is highly exposed to foreign sales primarily due to the global nature of technology businesses, which allows for easy distribution of digital products and services worldwide, and the pursuit of large international markets for growth opportunities.
This exposure is further amplified by the sector’s complex global supply chains and the inherent scalability of many tech offerings.
The materials sector is the second most exposed sector to foreign sales, and is made up of mining, chemicals, and forest product companies.
Looking at emerging market sales exposure specifically, the information technology sector is again the most exposed.
Learn More on the Voronoi App
To learn more about the S&P 500’s performance, check out this graphic that shows how the index fares after an interest rate cut.
-
Misc1 week ago
Mapped: Average IQ Score by State
-
United States2 weeks ago
Mapped: U.S. States That Work the Hardest
-
Green3 weeks ago
The Number of Earths Needed for Different Countries’ Lifestyles
-
Misc3 weeks ago
The Most Reliable Car Brands, According to Consumer Reports
-
Markets4 weeks ago
Mapped: U.S. States With the Most Million-Dollar Homes
-
Misc4 weeks ago
America’s Favorite Car Brands, by Generation
-
Markets2 weeks ago
Ranked: World’s Biggest Superpowers in 2024
-
Markets2 weeks ago
Government Debt Projections for G7 Countries (2024-2029F)